- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05000411
The Impact of Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling
The Impact of Traditional Chinese Medicine, Compound Danshen Dropping Pills (CDDP) on the Post-myocardial Infarction Ventricular Remodeling: A Multicentre, Randomized, Double-blind, Placebo-controlled, Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Progressive ventricular remodeling after acute anterior wall myocardial infarction(MI)is an important factor in the occurrence and death of heart failure. Angiotensin converting enzyme inhibitors and beta-blockers can ameliorate post-MI ventricular remodeling, but high-dose therapy can't be tolerable because of hemodynamic instability in the early stage of acute mycardial infarction(AMI). It is known that traditional Chinese medicine, compound Danshen dropping pills (CDDP) exerts protective effect on microcirculatory disturbance caused by ischemia-reperfusion injury and improves energy metabolism after acute myocardial ischemia. Experimental studies have shown CDDP may attenuate ventricular remodeling after myocardial infarction.
Methods:This study is designed to evaluate the efficacy and safety of CDDP in improving ventricular remodeling and cardiac function after acute anterior wall ST-Elevation MI(STEMI). 268 patients with acute anterior wall STEMI after primary Percutaneous Coronary Intervention (pPCI) are randomly assigned 1:1 to CDDP group(n=134) and control group(n=134) with follow-up of 24 weeks. Both groups are treated with standard therapy of STEMI, with the CDDP group administrating 20 tablets of CDDP before pPCI and 10 tablets three times a day after pPCI and the control group treated with placebo at the same time. The primary endpoint is 24-week echocardiographic including left ventricle ejection fraction (LVEF) , left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index (LVESVI).The secondary endpoint is the change in N terminal pro-B-type natriuretic peptide(NT-proBNP) level, arrhythmia and cardiovascular events (death, cardiac arrest or cardiopulmonary resuscitation, hospitalization due to heart failure or angina pectoris).
Discussion:This is the first prospective study that will demonstrate the impact of CDDP on ventricular remodeling and cardiac function in patients treated with pPCI for a first acute anterior wall STEMI .This study may provide novel insights of Traditional Chinese Medicine , CDDP to improve ventricular remodeling.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Recruiting
- First Affiliated Hospital of Nanjing Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 18-75 years, gender unlimited;
- According to the guidelines for diagnosis and treatment of acute ST segment elevation myocardial infarction (2019), patients with acute anterior ST segment elevation myocardial infarction were diagnosed;
- Patients with primary acute myocardial infarction;
- Patients who completed PCI reperfusion treatment within 12 hours after the onset of the disease;
- Patients categorized as Classes I, II or III according to Killip classification on admission;
- Subjects participated in the study voluntarily and signed informed consent.
Exclusion Criteria:
- Patients with previous cardiac insufficiency caused by other diseases (valvular heart disease, congenital heart disease, pericardial disease, arrhythmia, other non cardiac causes);
- The patients underwent coronary artery bypass graft(CABG) within 12 weeks;
- Patients undergoing cardiac resynchronization;
- Patients with left ventricular outflow tract obstruction;
- Patients with myocarditis;
- Patients with uncontrolled severe arrhythmia;
- Patients with aortic aneurysm;
- Patients with serious liver, kidney, blood system, mental disease or systemic disease;
- Significant liver and kidney dysfunction (ALT > 2.0 times the upper limit of normal value; creatinine > 1.5 times the upper limit of normal value);
- Patients with serum potassium > 5.5mmol/l;
- Uncontrolled hypertension (higher than 180 / 110mmhg);
- Pregnant or lactating women;
- Patients allergic to compound Danshen Dropping Pills; 1
- Patients participating in clinical studies of other drugs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group
|
The patients in this group are treated with 20 tablets of Compound Danshen Dropping Pills (CDDP) before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI.
|
Placebo Comparator: Control group
|
The patients in this group take 20 tablets of placebo before primary Percutaneous Coronary Intervention (pPCI) and 10 tablets three times a day after pPCI .
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ultrasonic cardiogram:left ventricle ejection fraction (LVEF)
Time Frame: Week 24
|
LVEF refers to the percentage of stroke output to left ventricular end-diastolic volume and it can be examined by ultrasonic cardiogram.
|
Week 24
|
ultrasonic cardiogram:left ventricular end-diastolic volume index (LVEDVI)
Time Frame: Week 24
|
LVEDVI(ml/m2)=left ventricular end-diastolic volume(ml)/body surface area(m2).
It can be examined by ultrasonic cardiogram.
|
Week 24
|
ultrasonic cardiogram:left ventricular end-systolic volume index (LVESVI)
Time Frame: Week 24
|
LVESVI(ml/m2)=left ventricular end-systolic volume(ml)/body surface area(m2).
It can be examined by ultrasonic cardiogram.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
N terminal pro-B-type natriuretic peptide(NT-proBNP )decline level
Time Frame: Day 0/ Day 3/ Day 7/ Week 4/ Week 24/ Week 48
|
N terminal pro-B-type natriuretic peptide(NT-proBNP )is obtained by blood test.
|
Day 0/ Day 3/ Day 7/ Week 4/ Week 24/ Week 48
|
Adverse cardiovascular events
Time Frame: Day 0 to Week 48
|
Day 0 to Week 48
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CDDP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
Clinical Trials on Compound Danshen Dropping Pills (CDDP)
-
Qilu Hospital of Shandong UniversityRecruitingMicrovascular AnginaChina
-
Ruijin HospitalNot yet recruiting
-
Tasly Pharmaceuticals, Inc.CompletedAcute Mountain SicknessChina
-
Tasly Pharmaceuticals, Inc.CompletedAngina PectorisCanada, United States, Russian Federation, Belarus, Georgia, Mexico, Ukraine
-
Tasly Pharmaceuticals, Inc.UnknownNon-proliferative Diabetic RetinopathyChina
-
Chinese Academy of Medical Sciences, Fuwai HospitalTianjin Tasly Pharmaceutical Co., LtdUnknown
-
Wanbangde Pharmaceutical Group Co., LTDThe First Affiliated Hospital, Guangzhou University of Traditional Chinese...UnknownStable Angina Pectoris Associated With DepressionChina
-
West China HospitalUnknownEssential Hypertension | Coronary Heart DiseaseChina
-
Taizhou Fourth People's HospitalShanghai 10th People's HospitalUnknownInflammation | Angina, StableChina
-
Peking University Third HospitalNot yet recruitingAcute Myocardial Infarction